Chemotherapy-associated thrombosis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease, involving complex interactions between individuals (including their hemostatic system and genetic predispositions) and their environmental exposures. Active malignancy is a well recognized risk factor for VTE and accounts for almost 20% of incident VTE events occurring in the community [1], with chemotherapy independently adding to that risk [2, 3]. As compared with the general population, the risk of VTE is increased fourfold in patients with cancer and this risk is further elevated to more than sixfold when these patients are receiving chemotherapy [2]. Moreover, there is a twofold increase in recurrent VTE in patients with malignancy and a fourfold increase in this risk for those receiving chemotherapy [2]. In addition, the risk of VTE varies by cancer type and stage [3-6]. The type of chemotherapy administered, hormonal treatments, immunomodulating and anti-angiogenesis agents (e.g., thalidomide, lenalidomide, bevacizumab), and supportive therapy with hematopoietic growth factors like recombinant human erythropoietins have been implicated in alterations in hemostasis and with increased VTE risk.

Original languageEnglish (US)
Pages (from-to)181-206
Number of pages26
JournalCancer Treatment and Research
Volume148
DOIs
StatePublished - 2009

Fingerprint

Venous Thromboembolism
Thrombosis
Drug Therapy
Neoplasms
Thalidomide
Environmental Exposure
Hemostatics
Genetic Predisposition to Disease
Erythropoietin
Hemostasis
Pulmonary Embolism
Venous Thrombosis
Intercellular Signaling Peptides and Proteins
Therapeutics
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapy-associated thrombosis. / Ashrani, Aneel Arjun; Rajkumar, S Vincent.

In: Cancer Treatment and Research, Vol. 148, 2009, p. 181-206.

Research output: Contribution to journalArticle

@article{7d4826e9a2e948f6ad370a49e3f3a799,
title = "Chemotherapy-associated thrombosis",
abstract = "Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease, involving complex interactions between individuals (including their hemostatic system and genetic predispositions) and their environmental exposures. Active malignancy is a well recognized risk factor for VTE and accounts for almost 20{\%} of incident VTE events occurring in the community [1], with chemotherapy independently adding to that risk [2, 3]. As compared with the general population, the risk of VTE is increased fourfold in patients with cancer and this risk is further elevated to more than sixfold when these patients are receiving chemotherapy [2]. Moreover, there is a twofold increase in recurrent VTE in patients with malignancy and a fourfold increase in this risk for those receiving chemotherapy [2]. In addition, the risk of VTE varies by cancer type and stage [3-6]. The type of chemotherapy administered, hormonal treatments, immunomodulating and anti-angiogenesis agents (e.g., thalidomide, lenalidomide, bevacizumab), and supportive therapy with hematopoietic growth factors like recombinant human erythropoietins have been implicated in alterations in hemostasis and with increased VTE risk.",
author = "Ashrani, {Aneel Arjun} and Rajkumar, {S Vincent}",
year = "2009",
doi = "10.1007/978-0-387-79962-9_11",
language = "English (US)",
volume = "148",
pages = "181--206",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Chemotherapy-associated thrombosis

AU - Ashrani, Aneel Arjun

AU - Rajkumar, S Vincent

PY - 2009

Y1 - 2009

N2 - Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease, involving complex interactions between individuals (including their hemostatic system and genetic predispositions) and their environmental exposures. Active malignancy is a well recognized risk factor for VTE and accounts for almost 20% of incident VTE events occurring in the community [1], with chemotherapy independently adding to that risk [2, 3]. As compared with the general population, the risk of VTE is increased fourfold in patients with cancer and this risk is further elevated to more than sixfold when these patients are receiving chemotherapy [2]. Moreover, there is a twofold increase in recurrent VTE in patients with malignancy and a fourfold increase in this risk for those receiving chemotherapy [2]. In addition, the risk of VTE varies by cancer type and stage [3-6]. The type of chemotherapy administered, hormonal treatments, immunomodulating and anti-angiogenesis agents (e.g., thalidomide, lenalidomide, bevacizumab), and supportive therapy with hematopoietic growth factors like recombinant human erythropoietins have been implicated in alterations in hemostasis and with increased VTE risk.

AB - Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease, involving complex interactions between individuals (including their hemostatic system and genetic predispositions) and their environmental exposures. Active malignancy is a well recognized risk factor for VTE and accounts for almost 20% of incident VTE events occurring in the community [1], with chemotherapy independently adding to that risk [2, 3]. As compared with the general population, the risk of VTE is increased fourfold in patients with cancer and this risk is further elevated to more than sixfold when these patients are receiving chemotherapy [2]. Moreover, there is a twofold increase in recurrent VTE in patients with malignancy and a fourfold increase in this risk for those receiving chemotherapy [2]. In addition, the risk of VTE varies by cancer type and stage [3-6]. The type of chemotherapy administered, hormonal treatments, immunomodulating and anti-angiogenesis agents (e.g., thalidomide, lenalidomide, bevacizumab), and supportive therapy with hematopoietic growth factors like recombinant human erythropoietins have been implicated in alterations in hemostasis and with increased VTE risk.

UR - http://www.scopus.com/inward/record.url?scp=77953681594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953681594&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-79962-9_11

DO - 10.1007/978-0-387-79962-9_11

M3 - Article

VL - 148

SP - 181

EP - 206

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -